GlassScriptPhysician profile
Barry M Littlejohn
NPI 1215010210
$321.46
in general payments reported to CMS, 2019-2025
9 companies · $78.06 in 2025
The $78.06 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $31.08 · 2022: $58.22 · 2023: $135 · 2024: $18.87 · 2025: $78.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $232.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baudax Bio INC. | $62.64 | 2020-2022 | |
| Sanofi Pasteur INC. | $54.77 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $49.41 | 2023 | Rebyota |
| Daiichi Sankyo INC. | $34.79 | 2023 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $29.08 | 2023 | Flumist Quadrivalent |
| Exact Sciences Corporation | $27.00 | 2025 | The Cologuard Plus Collection Kit |
| Minerva Surgical, INC | $22.95 | 2025 | |
| Glaxosmithkline, LLC. | $21.95 | 2023 | Arexvy, Bexsero, Shingrix |
| Merck Sharp & Dohme LLC | $18.87 | 2024 | Gardasil 9, Gardasil, Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Littlejohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.